阿波贝克
生物
突变
遗传学
癌变
突变
癌症
突变率
种系突变
基因组
体细胞
癌症研究
基因
作者
Tony M. Mertz,Christopher D. Collins,Madeline A. Dennis,Margo Coxon,Steven A. Roberts
标识
DOI:10.1146/annurev-genet-072920-035840
摘要
The initiation, progression, and relapse of cancers often result from mutations occurring within somatic cells. Consequently, processes that elevate mutation rates accelerate carcinogenesis and hinder the development of long-lasting therapeutics. Recent sequencing of human cancer genomes has identified patterns of mutations, termed mutation signatures, many of which correspond to specific environmentally induced and endogenous mutation processes. Some of the most frequently observed mutation signatures are caused by dysregulated activity of APOBECs, which deaminate cytidines in single-stranded DNA at specific sequence motifs causing C-to-T and C-to-G substitutions. In humans, APOBEC-generated genetic heterogeneity in tumor cells contributes to carcinogenesis, metastasis, and resistance to therapeutics. Here, we review the current understanding of APOBECs' role in cancer mutagenesis and impact on disease and the biological processes that influence APOBEC mutagenic capacity.
科研通智能强力驱动
Strongly Powered by AbleSci AI